Expert Review of Clinical Pharmacology

Papers
(The H4-Index of Expert Review of Clinical Pharmacology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion68
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed47
Reducing the risk of death – a possible outcome in COPD patients45
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis39
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy38
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies36
A review of current and emerging therapies in breast cancer: implications for older adults35
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome33
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?32
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review31
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions31
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?30
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis28
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion28
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis27
Clinical pharmacology of antiplatelet drugs27
Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools27
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments27
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial25
Fetal safety of medications used in treating infertility25
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection24
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy22
The pharmacotherapeutics of sarcoidosis22
0.16286993026733